Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes  Denis Jullien, Jörg C. Prinz, Frank O. Nestle  Journal of Investigative Dermatology  Volume 135, Issue 1, Pages 31-38 (January 2015) DOI: 10.1038/jid.2014.295 Copyright © 2015 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 1 Molecular structures of biologic drugs used to treat psoriasis. Neutralizing anti-drug antibodies (ADAs) bind to murine epitopes and idiotopes located at the antigen-binding site and prevent fixation of the therapeutic agent to its target, reducing its clinical efficacy. In contrast, ADAs that bind to allotopes and human neo-antigens at the hinge of fusion proteins are usually non-neutralizing. Both neutralizing and non-neutralizing ADAs may reduce drug efficacy through the formation of immune complexes, which may lead to increased drug clearance. Journal of Investigative Dermatology 2015 135, 31-38DOI: (10.1038/jid.2014.295) Copyright © 2015 The Society for Investigative Dermatology, Inc Terms and Conditions